Table 1.

Available therapeutic options in NAFLD

	Liver enzymes	Steatosis	Inflammation	Fibrosis	Adverse events	Beneficial clinical aspects
GLP1 receptor agonists	+	+	+	+	Gastrointestinal	Weight loss, reduction of CV events
SGLT2 inhibitors	+	+	?	?	Genitourinary infections, dehydration	Reduction of CV events, nephron-protection, weight loss
Glitazones	+	+	+	+	Weight gain (mild), oedema, heart failure, bone fractures	reduction of CV events
Bariatric surgery	+	+	+	+	Invasive procedure, malnutrition	Weight loss

CV, cardio vascular; GLP1, glucagon-like peptide 1; SGLT2, sodium–glucose transporter 2.